Zoetis: Unleashing Margin Expansion; Initiate Strong Buy
We initiate coverage on Zoetis with a Strong Buy rating and a $219.26 price target, driven by explosive growth in companion animal products and structural margin expansion. Zoetis's leadership in companion animal therapeutics, particularly with Librela and Simparica, supports our above-consensus EPS forecasts of $6.12 for FY25 and $6.80 for FY26. The divestiture of lower-margin feed additives enables strategic R&D reinvestment, bolstering innovation and operational growth, while maintaining competitive moats in key markets.
Zoetis (ZTS) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates
Get a deeper insight into the potential performance of Zoetis (ZTS) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Zoetis (ZTS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Zoetis (ZTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zoetis Gears Up to Report Q1 Earnings: Here's What to Expect
ZTS' higher companion animal product sales are likely to have driven revenues in first-quarter 2025 in both the United States and International segments.
1 Superstar Dividend Growth Stock to Buy if the Market Crashes
The stock market has entered a new period of increased uncertainty and volatility following the Trump Administration's desire to reshape America's trade policies. While the market hasn't crashed outright, it has experienced multiple sessions of sharp losses, as well as dramatic rebounds.
Zoetis (ZTS) Advances But Underperforms Market: Key Facts
In the most recent trading session, Zoetis (ZTS) closed at $152.30, indicating a +0.92% shift from the previous trading day.
This Magnificent Dividend Stock Has Increased Its Payouts by 500% in 10 Years
There are many dividend stocks on equity markets, but not all are attractive to income investors. Those that go beyond paying a quarterly payout but also consistently raise their dividends -- all while having robust businesses that can support their dividend programs for a long time -- are the ones income-seekers want.
Zoetis' Stock Is About as Cheap as It's Ever Been. 1 Thing to Know Before You Buy.
Shares in animal pharmaceutical company Zoetis (ZTS 0.14%) have been under a cloud since the release of the company's fourth-quarter earnings report in mid-February. The Q4 numbers were fine, but the company's revenue guidance fell short of expectations.
Zoetis: Lots Of Growth Opportunities For This High-Quality Compounder
Zoetis is currently cheap from a historical perspective, presenting a potential buying opportunity. The company operates in a growing animal healthcare market, benefiting from trends like pet humanization and medicalization, ensuring long-term growth. ZTS has a strong track record of market outperformance, impressive margins, and a high ROIC, making it a high-quality company.
Zoetis (ZTS) Stock Declines While Market Improves: Some Information for Investors
Zoetis (ZTS) closed the most recent trading day at $163.03, moving -0.08% from the previous trading session.
Why Zoetis (ZTS) Dipped More Than Broader Market Today
The latest trading day saw Zoetis (ZTS) settling at $160.06, representing a -1% change from its previous close.
Zoetis: Focusing On The High Margin Segments
The recent divestiture of the MFA segment improves margins and returns on capital. Zoetis is focusing on more profitable segments like genetics and companion animals. The recently updated Librela label includes adverse effects and urges practitioners to discuss potential adverse reactions with clients.
